The delivery of nitric oxide through liposomes as next generation drug eluting stents and vascular interventions
The implantation of metallic stents after percutaneous coronary intervention is one form of surgical intervention to combat coronary artery disease. A major drawback is the re-narrowing or restenosis, due to the proliferation of smooth muscle cells, of the artery after a bare metal stent implanta...
Saved in:
Main Author: | |
---|---|
Other Authors: | |
Format: | Thesis-Doctor of Philosophy |
Language: | English |
Published: |
Nanyang Technological University
2022
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/156898 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Summary: | The implantation of metallic stents after percutaneous coronary intervention is one
form of surgical intervention to combat coronary artery disease. A major drawback is
the re-narrowing or restenosis, due to the proliferation of smooth muscle cells, of the
artery after a bare metal stent implantation. Stents eluting limus based drugs was then
introduced to combat restenosis but resulted in new issues such as stent thrombosis.
The problem lies with the non-selective nature of these drugs which inhibited the
proliferation of both smooth muscle cells and endothelial cells, causing a delay in
healing. This delayed healing also introduced the need for patients to undergo
antiplatelet therapy which also brings forth new challenges. Hence to address the
primary problem of restenosis, nitric oxide stents were explored in the past. Nitric
oxide (NO) is capable of selectively inhibiting the proliferation of smooth muscle
cells only, allowing for endothelial cells to proliferate and migrate. In therapy, this
would promote faster and better healing for the patients. However, studies on NO
releasing stents were limited and those reported had short nitric oxide release profiles.
In three main studies, this thesis attempts to fabricate a nitric oxide releasing stent. To
start off, three different nitric oxide donors were first examined individually. As most
NO donors are water soluble, they cannot be blended with conventional polymers in
organic solvents for stent spray coating. Thus, the strategy was to select one stable
donor and have it encapsulated into liposomes. After which, the liposomes loaded
with the donor would be coated onto the stent. Characterisation of theses donors were
done via UV-VIS or with the Griess Reagent kit. It was found that endogenous s-
nitrosoglutathione (GSNO) was the most stable of the three donors examined and
hence was selected to be the NO donor for the stent. During the examination process,
it was also found that the incorporation of NO conjugated lipids into a poly (D, L-
lactide-co-glycolide) lactide:glycolide (50:50) (PLGA 50:50) blended was able to
prolong the release of NO slightly. The blended film had PLGA acting as a matrix to
slow down the rate of NO release via the caging mechanism. However, this
fabrication was limited by significant NO loss during the drying process.
Four different methods for the encapsulation of GSNO into liposomes were then
explored. Of the different methods, inverted emulsion was found to be able to
improve the partition coefficient of the molecules. An NO release profile was then
established to confirm that GSNO had successfully been loaded. This successful
encapsulation meant that the GSNO can be incorporated onto a metallic stent
Finally, these GSNO loaded liposomes were then coated onto metallic stents and
substrates. The layer-by-layer technique was employed to achieve this. At first, it was
found that the low viscosity of poly-l-arginine (PLA) could not adhere onto the
metallic stent. The deposition of poly dopamine helped overcome this hurdle. A total
of two methods of conducting the LBL coating were examined, the pipetting followed
vacuum evaporation method and the dip coating method. Ultimately, the dip coating
method was found to have better stent finishing, with up to 10 layers of PLA and
GSNO liposomes coated onto the stent. In addition, there was no significant
delamination observed during the release studies. The coated stents were able to
achieve a NO release profile of more than 14 days, which was longer than those
reported in literature.
The exploration of unconventional means of drug encapsulation for liposomes and
then incorporating these liposomes onto the stents via dip coated LBL, pathed the way
for a NO releasing stent. By stacking layers of GSNO loaded liposomes upon PLA
polymer and vice versa, more GSNO could be loaded onto the stent and the release of
NO was extended. Such means of fabrication would hopefully encourage others to
pursue the use of NO for future drug eluting stents. |
---|